Could Teva Pharmaceutical Industries Ltd (ADR) Decline After Today’s Tip From Option Traders?

 Could Teva Pharmaceutical Industries Ltd (ADR) Decline After Today's Tip From Option Traders?

In today’s session Teva Pharmaceutical Industries Ltd (ADR) (TEVA) registered an unusually high (2,846) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the March, 2017 call, expecting serious TEVA increase. With 2,846 contracts traded and 37704 open interest for the Mar, 17 contract, it seems this is a quite bullish bet. The option with symbol: TEVA170317C00040000 closed last at: $1.63 or 6.3% down. About 1.43M shares traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 31.44% since April 28, 2016 and is downtrending. It has underperformed by 37.37% the S&P500.

Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on February, 9. They expect $1.39 EPS, up 8.59% or $0.11 from last year’s $1.28 per share. TEVA’s profit will be $1.38 billion for 6.67 P/E if the $1.39 EPS becomes a reality. After $1.28 actual EPS reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 8.59% EPS growth.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Out of 22 analysts covering Teva Pharma (NYSE:TEVA), 13 rate it a “Buy”, 0 “Sell”, while 9 “Hold”. This means 59% are positive. $86 is the highest target while $40 is the lowest. The $66.07 average target is 78.28% above today’s ($37.06) stock price. Teva Pharma has been the topic of 40 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Maxim Group given on Wednesday, November 16. Guggenheim upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Friday, December 4 to “Buy” rating. The firm has “Buy” rating by HSBC given on Monday, July 18. The stock has “Neutral” rating given by Nomura on Tuesday, September 29. Morgan Stanley downgraded the shares of TEVA in a report on Wednesday, November 16 to “Equal-Weight” rating. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Thursday, August 25 by Mizuho. The stock has “Buy” rating given by Argus Research on Tuesday, July 28. The rating was maintained by Oppenheimer on Thursday, July 14 with “Outperform”. The rating was upgraded by Credit Suisse to “Outperform” on Monday, October 31. Bank of America downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, November 7 to “Neutral” rating.

According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.”

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The company has a market cap of $36.78 billion. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It has a 21.41 P/E ratio. The Firm operates through two divisions: Generic medicines and Specialty medicines.

TEVA Company Profile

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.

More news for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) were recently published by: Investorplace.com, which released: “Marijuana News: Teva Pharmaceuticals Industries Ltd (ADR) Signs Cannabis …” on November 28, 2016. Investorplace.com‘s article titled: “Why Nokia Corp (ADR) (NOK), Teva Pharmaceutical Industries Ltd (ADR) (TEVA …” and published on November 15, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment